The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
Open accessAbstract
Hereditary ovarian cancer accounts for at least 5% of the estimated 22,000 new cases of this disease during 2009. During this same time, over 15,000 will die from malignancy ascribed to ovarian origin. The bulk of these hereditary cases fits the hereditary breast–ovarian cancer syndrome, while virtually all of the remainder will be consonant with the Lynch syndrome, disorders which are autosomal dominantly inherited. Advances in molecular genetics have led to the identification of BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast–ovarian cancer syndrome, and mutations in mismatch repair genes, the most common of which are MSH2 and MLH1, which predispose to Lynch syndrome. These discoveries enable relatively certain diagnosis, limited only by their variable penetrance, so that identification of mutation carriers through a comprehensive cancer family history might be possible. This paper reviews the subject of hereditary ovarian cancer, with particular attention to its molecular genetic basis, its pathology, and its phenotypic/genotypic heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“…in a significant fraction of sporadic occurrences, and molecular pathology studies, such as these, may be the linchpin between heritable ovarian cancers and those which occur in the general population (Baldwin et al., 2000; Chen et al., 2006, 2008; Esteller et al., 2000; Hilton et al., 2002).”
BackgroundShih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair
Marsischky, G. T., Filosi, N., Kane, M. F., & Kolodner, R. (1996) · Genes & Development · doi:10.1101/gad.10.4.407 · Cited by 581
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Saam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Hereditary and Familial Colon Cancer
Jasperson, K. W., Tuohy, T. M., Neklason, D. W., & Burt, R. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.054 · Cited by 1,312
Metadata
- Authors
- Lynch, H. T., Casey, M. J., Snyder, C. L., Bewtra, C., Lynch, J. F., Butts, M., & Godwin, A. K.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2009-02-21
- Volume
- 3
- Issue
- 2
- Pages
- 97-137
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2168804588
- Cited by
- 208
- References
- 11
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. https://app.cochat.ai/papers/10.1016/j.molonc.2009.02.004
- The paper
- Lynch, H. T., Casey, M. J., Snyder, C. L., Bewtra, C., Lynch, J. F., Butts, M., & Godwin, A. K. (2009). Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Molecular Oncology. https://doi.org/10.1016/j.molonc.2009.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.